Lyell Immunopharma, Inc.
Moat Score — Lyell Immunopharma, Inc.
Total Moat Score
9 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Lyell's c-Jun overexpression, NR4A3 gene knockout, and Epi-R manufacturing protocol are proprietary, patent-protected cell-engineering technologies with real reported efficacy signals in both a blood cancer (Ronde-cel) and, unusually, a solid tumor (LYL273) -- genuine intellectual property, not yet converted into a commercial moat. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Autologous CAR T manufacturing is inherently expensive and cannot be mass-produced like a conventional drug; Lyell's dedicated LyFE Manufacturing Center gives it capacity but not a structural cost advantage over other cell-therapy makers. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | With no approved product, Lyell has no current pricing power of its own; if Ronde-cel reaches the market it would likely be priced in line with the six-figure price points of approved CAR T therapies, but that is speculative, not realized. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | A one-time autologous cell therapy for an individual patient has no network effect between users, prescribers, or sites of care. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Because CAR T is a one-time treatment rather than a recurring therapy, there is no ongoing 'switching' relationship with a payer or patient to lock in once a product is approved; any durability comes from clinical outcomes, not contractual stickiness. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | The ~73,000 sq. ft. LyFE Manufacturing Center, built to produce 1,200+ patient-specific products per year, represents a real capital and expertise barrier to entry for new cell-therapy entrants, though several well-funded competitors already operate at comparable or larger scale. |